Skip to main content
OpenTrials
Completed

NCT Number: NCT01633411

Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium

This is a feasibility study without a primary study hypothesis or statistical comparison.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Barrett's Esophagus Barrett Esophagus Digestive System Diseases Esophageal Diseases Gastrointestinal Diseases Neoplasms Precancerous Conditions

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Academic Medical Center Amsterdam, Amsterdam, Netherlands

Loading trial locations.

About this study

The purpose of this study is to assess the safety, feasibility, and performance of the C2 Focal Cryoablation Device in patients with Barrett's Esophagus (BE). At 6 to 8 weeks, the patient will receive a follow-endoscopy to assess stricture formation along with biopsy samples taken.

Post-operative pain will be noted. Additionally, biopsy samples will be evaluated for the presence of residual Barrett's Esophagus. Through evaluation of the histological results, treatment parameters for the ablation of human esophageal epithelium will be better understood.

Evaluations include, but are not limited to the following:

  • Deployment ease/scope compatibility.
  • Device malfunctions.
  • Time of catheter deployment.
  • Adverse events.
  • Stricture formation at 6 to 8 weeks.
  • Patient Pain.
  • Histological evaluation of treatment zone at 6 to 8 weeks for presence of residual Barrett's Esophagus.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients scheduled for ablation, EMR, and/or surveillance for BE (with or without dysplasia). Patient is 18 to 80 years of age at the time of consent (inclusive).
  • Patient has provided written Informed Consent (IC) using an Informed Consent Form (ICF) that has been approved by the Institution's reviewing IRB/EC.
  • Patient is willing and able to comply with all Clinical Investigation Plan (CIP) requirements.
  • Patient is deemed operable per standard institutional criteria.

Exclusion criteria

  • Patient with endoscopically active inflammation in the treatment zone
  • Esophageal stenosis preventing advancement of a therapeutic endoscope and/or within 4 cm of treatment zone.
  • Patient has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post treatment instructions or follow-up guidelines.
  • Patient refuses or is unable to provide written informed consent.
  • Patients that are pregnant.

Treatment and study plan

Focal Cryoballoon Ablation System - 6 seconds

Device

Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device "intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."

Focal Cryoballoon Ablation System - 8 seconds

Device

Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device "intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."

CryoBalloon Focal Ablation System - 10 seconds

Device

Ablation of Barrett's Esophagus using the Focal CryoBalloon Ablation System. The System is a Class II device "intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications".

Primary outcomes

  1. Esophageal Stricture

    Time frame: 6 to 8 Weeks

    Stricture formation is defined as none, mild (non-circumferential stenosis allowing easy passage of diagnostic endoscope), moderate (circular stenosis allowing passage of diagnostic endoscope), and severe (any stenosis preventing the passage of a diagnostic scope).

Secondary outcomes

  1. Post-procedure pain relative

    Time frame: Pre-ablation,12 hrs post ablation, 2 days (+ or - 1 day)

    A secondary objective of the study is to determine patient comfort post-procedure. Pain scores are measured on a numerical pain intensity scale (0 to 10). Patients is asked to score pain level in the treatment area and swallowing.

  2. Presence of Residual Barrett's Esophagus

    Time frame: 6 to 8 weeks

    Esophageal tissue subjected to ablation via the CryoBalloon Focal Ablation System will be submitted for histological evaluation. The evaluation will include:

    • detailed description of the presence of Barrett's Esophagus and/or squamous mucosa.
    • estimate of percentage of residual Barrett's in each sample
    • the detailed description of any residual injury at all levels within the sample.

Sponsors and collaborators

Lead sponsor

Pentax Medical

Industry

Registry information

Important dates

Study start
2011
Primary completion
2014
Study completion
2014
First posted
Jul 4, 2012
Registry last updated
Apr 28, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.